More Diagnostics, a trusted leader in in vitro diagnostic quality controls for over 30 years, is proud to announce the debut of two advanced cardiac-focused products: a High-Sensitivity Troponin Control and a Clinical Cardiac Control. These additions strengthen the company's commitment to delivering superior tools for precision medicine in cardiovascular care.
Key highlights
- High-Sensitivity Troponin Control: Supports labs in detecting minute troponin elevations with unmatched stability and performance for myocardial infarction screening.
- Clinical Cardiac Control: A versatile control tailored to monitor a panel of cardiac biomarkers in routine and emergency settings, ensuring consistent accuracy in results.
- Regulatory Confidence: Both products align with ISO 13485:2016 standards and FDA specifications, reinforcing reliability in clinical decision-making.
More Diagnostics Inc works closely with industry partners to:
- Tackle medical misinformation with precise cardiac diagnostics
- Respond to rising cardiovascular risk with robust lab solutions
"We take great pride in ensuring that our end users place their trust in the precision and accuracy of our products. Products 125 and 155 represent MDI's reentry into the field of cardiac diagnostics. Our goal is to instill confidence in laboratories, not only in the reliability of the results but also through the assurance provided by our Quality Controls. "
How microRNA is transforming science: From discovery to diagnostics